Name (Synonyms) | Correlation | |
---|---|---|
drug431 | Favipiravir Wiki | 0.32 |
drug957 | Remdesivir Wiki | 0.30 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.11 |
D007239 | Infection NIH | 0.07 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The objective of this study is to evaluate the efficacy of oral favipiravir compared with SOC in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with uncomplicated COVID-19 disease.
Description: Time in days from randomization to a negative result of nasopharyngeal and/or oropharyngeal and/or salivary swab.
Measure: Time until cessation of oral shedding of SARS-CoV-2 virus Time: Up to 28 daysDescription: Clinical worsening will be determined by clinician assessment.
Measure: Count of participants with clinical worsening of COVID-19 disease Time: Up to 28 daysDescription: Viral load will be assessed as the TCID50 (Median Tissue Culture Infectious Dose) over time.
Measure: Sars-CoV-2 viral load Time: Up to 28 daysDescription: Cmax is a pharmacokinetic parameter that measures the maximum concentration of drug in plasma.
Measure: Cmax of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)Description: Cmin is a pharmacokinetic parameter that measures the minimum concentration of drug in plasma.
Measure: Cmin of favipiravir Time: Days 1 and 10 (samples taken 30 minutes prior to and 1 hour following favipiravir administration)